ArticleExperimental and therapeutic medicine2021
Value of GastroPanel in the diagnosis of atrophic gastritis.
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- The LGR5/TFF2 ratio as a stem cell biomarker predicts high-risk status in chronic atrophic gastritis: a retrospective cohort study.BMC gastroenterology · 2026Article
- Differential impacts of Helicobacter pylori antibody typing on gastric secretory function: a cross-sectional study based on serum biomarkers.BMC gastroenterology · 2026Observational
- Diagnostic value of a serum four-biomarker panel for atrophic gastritis in women under 60 years of age.Frontiers in medicine · 2026Article
- Role of Serum Pepsinogen Tests in Detection of Gastric Atrophy, Intestinal Metaplasia, Gastric Adenoma, and Gastric Cancer in South Korea.Gut and liver · 2025Article
- Assessing gastric cancer risk using the OLGA and OLGIM systems in Republic of Moldova.Frontiers in medicine · 2025Article
- Review
- Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.Cancer biomarkers : section A of Disease markers · 2024Article
- Pepsinogen I, pepsinogen II, gastrin-17, andArchives of medical science : AMS · 2024Article
- Diagnostic performance of the normal range of gastrin calculated using strict criteria based on a combination of serum markers and pathological evaluation for detecting gastritis: a retrospective study.BMC gastroenterology · 2023Article
- The central role of gastrin in gastric cancer.Frontiers in oncology · 2023Review
- Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis andMiddle East journal of digestive diseases · 2023Article
- Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), considered as precursor of the intestinal type of gastric cancer, is of growing interest. The combination of pepsinogen (PG), gastrin-17 (G17) and anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.